Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Investment company liquidity – steady as she goes, but could be better
19th Mar 2024
NB Private Equity Partners
Value creation in a higher-rate environment
7th Mar 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
93: How to be a contrarian venture capital investor and making taboo investments | Will Gibbs of Octopus Ventures
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
Shield Therapeutics Plc
Life Sciences
Accelerating effectiveness of enlarged sales team
By
Dr Martin Hall
15 Nov 2023
Tissue Regenix
Life Sciences
Continuation of the positive momentum
By
Dr Martin Hall
18 Sep 2023
Stay up-to-date with the latest research
Sign up to our newsletter
Shield Therapeutics Plc
Life Sciences
Accrufer Rx momentum gathering
By
Dr Martin Hall
25 Jul 2023
International Biotechnology Trust
Life Sciences
Industry M&A remains a key driver
By
Dr Martin Hall
10 Jul 2023
o2h Ventures
Life Sciences
The o2h Human Health EIS Knowledge Intensive Fund
29 Jun 2023
Shield Therapeutics Plc
Life Sciences
Reassuring 1Q’23 Accrufer prescriptions
By
Dr Martin Hall
17 May 2023
Tissue Regenix
Life Sciences
Turning profitable and cash-generative
By
Dr Martin Hall
05 Apr 2023
Advanced Oncotherapy
Life Sciences
Understanding the significance of 230MeV
By
Dr Martin Hall
17 Jan 2023
Shield Therapeutics Plc
Life Sciences
Positioned for growth and profitability
By
Dr Martin Hall
13 Jan 2023
Life Sciences
Hardman & Co Healthcare Index
By
Dr Martin Hall
06 Jan 2023
International Biotechnology Trust
Life Sciences
Low FDA activity may drive further M&A
By
Dr Martin Hall
08 Dec 2022
1
2
3
...
21
Next